At Sanofi Genzyme, we manage global manufacturing operations with specialized facilities as part of our ongoing commitment to product quality and accessibility. We also partner with select contract manufacturing organizations to supplement our in-house production capacity.
Many of Sanofi Genzyme's products are biologics, which means their manufacture is a lengthy process involving delicate living cells that are highly sensitive to their environment and even the smallest of changes in the production process.
We were one of the industry’s earliest innovators in large-scale commercial production of therapeutic enzymes using recombinant DNA technology. Over the years, we’ve continued to develop our capabilities in these complex biologic production techniques, enabling us to create effective therapeutics for patients with diseases caused by missing or malfunctioning enzymes.
Sanofi Genzyme facilities also manufacture many different therapeutic products for other divisions within Sanofi that vary widely in the medical conditions they treat and in how they are made. We also make use of these diverse in-house manufacturing capabilities to manufacture experimental products across varied medical technology platforms for use in clinical trials – such as genetically engineered viral vectors to test potential gene therapies. Developing these production techniques during the research phase can help with the transition to commercialization should research yield an approved, marketable product.